Fibrobiologics, INC 10-Q quarterly reports

FibroBiologics reports Q2 2026 results with increased R&D spending, ongoing clinical trial delays, and a significant threat of Nasdaq delisting.

FibroBiologics reports a $5.0 million net loss for Q1 2026 while navigating going concern risks and advancing its fibroblast-based clinical pipeline.

FibroBiologics reported a significantly wider net loss in Q3 2025, driven by increased R&D expenses, while facing substantial doubt about its ability to continue as a going concern and Nasdaq delisting threats.

FibroBiologics, an early-stage cell therapy company, reported significant operating losses and a substantial accumulated deficit, raising going concern doubts and receiving a Nasdaq non-compliance notice, despite advancing its preclinical and clinical programs.

FibroBiologics' Q1 2025 results reveal continued operating losses as the company progresses with its fibroblast-based therapies and prepares for clinical trials.

FibroBiologics reported its Q3 2024 financial results, highlighting ongoing research and development efforts and a net loss of $8.1 million for the nine months ended September 30, 2024.

FibroBiologics reported a net income of $898 thousand for the three months ended June 30, 2024, a significant improvement compared to a net loss of $2.16 million in the same period last year, while the six month results showed a net loss of $7.562 million.

FibroBiologics, a cell therapy company, reported a net loss of $8.46 million for the first quarter of 2024, alongside updates on its clinical programs and financial position.